Resveratrol: SIRT1 Longevity Activator or Overhyped PAINS Artifact?
Once heralded as the premier red-wine polyphenol that activates sirtuins and mimics caloric restriction, resveratrol is now intensely contested regarding in vivo bioavailability, off-target fluorescence artifacts, and failure in non-obese human trials.
Position A: Potent Sirtuin & AMPK Modulator
Camp ADr. David Sinclair
Harvard Medical School
Resveratrol allosterically binds directly to SIRT1 at an N-terminal activation domain (Glu230), enhancing deacetylation of natural substrates like PGC-1alpha and FoxO3. In high-fat diet models, resveratrol prevented diet-induced obesity, improved insulin sensitivity, and extended survival. Micronized formulations with fat achieve therapeutic human plasma concentrations.
Position B: PAINS Compound with Negligible Bioavailability
Camp BDr. Brian Kennedy
National University of Singapore / Buck Institute
Resveratrol failed to extend lifespan in normal-diet mice across extensive NIA Interventions Testing Program (ITP) cohorts. Furthermore, original in vitro fluorophore-conjugated SIRT1 activation assays were revealed to be assay artifacts (PAINS). With oral bioavailability <1% due to rapid phase II glucuronidation and sulfation, taking grams of resveratrol yields gastrointestinal distress rather than sirtuin activation.